Das Denkmal Lafermiere's

Franz Hermann Lafermièren muistomerkki Ludvigsteinilla Monrepos'n puistossa. Muistomerkki on tyyliltään uusklassinen ja koostuu roomalaistyylisestä hautapatsaasta ja sen päällä olevasta uurnasta. Taustalla kallion päällä englantilaisen arkkitehdin Charles Heathcote Tathamin suunnittelema goottilaistyylinen linna Ludvigsburg torneineen.

Sciences et technologies émergentes : pourquoi tant de promesses?

Les technosciences (numériques, bio- et nanotechnologies, neurosciences, médecine personnalisée, biologie de synthèse) sont accompagnées de promesses fabuleuses à l'attention du public et des décideurs. L'économie des promesses qui en résulte affecte le régime de financement de la recherche et la gouvernance du changement sociotechnique. Elle crée de l'engouement, soutient la compétition scientifique, attire des ressources financières et légitime d'importantes dépenses publiques. Cet ouvrage met en évidence les cycles accélérés d'enthousiasme et de désillusion, les décalages entre horizons d'attente et les questions démocratiques qu'ils soulèvent. Fondé sur des recherches de terrain relevant de l'étude sociale des sciences et des techniques, de la philosophie et de l'histoire, il examine les formes alternatives d'organisation de la recherche, de participation citoyenne et de répartition des droits de propriété et des bénéfices, et montre qu'une forme de ralentissement des promesses, non des sciences, favoriserait l'articulation de ces dernières avec les besoins de la société. L'ambition des textes réunis ici est d'ouvrir le débat en langue française en interrogeant directement le régime des promesses technoscientifiques.

Third International Congress on Epilepsy, Brain, and Mind: Part 2.

Epilepsy is both a disease of the brain and the mind. Here, we present the second of two papers with extended summaries of selected presentations of the Third International Congress on Epilepsy, Brain and Mind (April 3-5, 2014; Brno, Czech Republic). Humanistic, biologic, and therapeutic aspects of epilepsy, particularly those related to the mind, were discussed. The extended summaries provide current overviews of epilepsy, cognitive impairment, and treatment, including brain functional connectivity and functional organization; juvenile myoclonic epilepsy; cognitive problems in newly diagnosed epilepsy; SUDEP including studies on prevention and involvement of the serotoninergic system; aggression and antiepileptic drugs; body, mind, and brain, including pain, orientation, the "self-location", Gourmand syndrome, and obesity; euphoria, obsessions, and compulsions; and circumstantiality and psychiatric comorbidities.

Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes.

Despite moderate improvements in outcome of glioblastoma after first-line treatment with chemoradiation recent clinical trials failed to improve the prognosis of recurrent glioblastoma. In the absence of a standard of care we aimed to investigate institutional treatment strategies to identify similarities and differences in the pattern of care for recurrent glioblastoma. We investigated re-treatment criteria and therapeutic pathways for recurrent glioblastoma of eight neuro-oncology centres in Switzerland having an established multidisciplinary tumour-board conference. Decision algorithms, differences and consensus were analysed using the objective consensus methodology. A total of 16 different treatment recommendations were identified based on combinations of eight different decision criteria. The set of criteria implemented as well as the set of treatments offered was different in each centre. For specific situations, up to 6 different treatment recommendations were provided by the eight centres. The only wide-range consensus identified was to offer best supportive care to unfit patients. A majority recommendation was identified for non-operable large early recurrence with unmethylated MGMT promoter status in the fit patients: here bevacizumab was offered. In fit patients with late recurrent non-operable MGMT promoter methylated glioblastoma temozolomide was recommended by most. No other majority recommendations were present. In the absence of strong evidence we identified few consensus recommendations in the treatment of recurrent glioblastoma. This contrasts the limited availability of single drugs and treatment modalities. Clinical situations of greatest heterogeneity may be suitable to be addressed in clinical trials and second opinion referrals are likely to yield diverging recommendations.

Radiographic adenoid evaluation: proposal of an objective parameter

Objective The objective of the present study was to evaluate current radiographic parameters designed to investigate adenoid hypertrophy and nasopharyngeal obstruction, and to present an alternative radiographic assessment method. Materials and Methods In order to do so, children (4 to14 years old) who presented with nasal obstruction or oral breathing complaints were submitted to cavum radiographic examination. One hundred and twenty records were evaluated according to quantitative radiographic parameters, and data were correlated with a gold-standard videonasopharyngoscopic study, in relation to the percentage of choanal obstruction. Subsequently, a regression analysis was performed in order to create an original model so the percentage of the choanal obstruction could be predicted. Results The quantitative parameters demonstrated moderate, if not weak correlation with the real percentage of choanal obstruction. The regression model (110.119*A/N) demonstrated a satisfactory ability to “predict” the actual percentage of choanal obstruction. Conclusion Since current adenoid quantitative radiographic parameters present limitations, the model presented by the present study might be considered as an alternative assessment method in cases where videonasopharyngoscopic evaluation is unavailable.